Invion Limited (ASX: IVX) has achieved a major regulatory milestone with the United States Food and Drug Administration (FDA) granting Orphan Drug Designation (ODD) to INV043 for the treatment of anal cancer. This recognition is more than just a regulatory tick—it represents a strategic shift in the company’s development pathway

When it comes to transforming cancer care, true innovation lies not just in killing the cancer, but in seeing it and feeling it less, and healing with more grace. In this quiet revolution, Invion Limited (ASX: IVX) is emerging as a serious contender.